Category Archives: Global News Feed

CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that The New England Journal of Medicine (NEJM) has published a second manuscript detailing positive results from the company’s two-part Phase 2 LILAC study, which evaluated litifilimab (also known as BIIB059), an investigational drug, in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). Results from the SLE portion of the study (Part A) published today show litifilimab met the study’s primary endpoint by significantly reducing total active joint count compared to placebo. Positive data from the CLE portion of the study were published in NEJM on July 28th, 2022.

Read more:
The New England Journal of Medicine Publishes Second Manuscript Reporting Positive Phase 2 Results for Biogen’s Litifilimab (BIIB059) in Lupus

Top-line findings will be presented Sept. 10 at the annual European Society for Medical Oncology (ESMO) Congress

See more here:
Elevar Therapeutics Announces Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival Versus Sorafenib in...

- Presentation at World ADC Conference in San Diego -

Visit link:
CytomX Therapeutics Presents Overview of Conditionally-Activated Antibody-Drug Conjugate (ADC) Programs Including Next Generation EpCAM-Targeting...

Anticipated Cash Resources to be used to Advance Biolog-id Value Chain Optimization Platform for Blood Products and other Biologics Anticipated Cash Resources to be used to Advance Biolog-id Value Chain Optimization Platform for Blood Products and other Biologics

Read more:
Biolog-id and Genesis Growth Tech Acquisition Corp. Announce Execution of Business Combination Agreement for Proposed Merger to Create Publicly Listed...

— Fruquintinib treatment reduced the risk of death by 34% in metastatic colorectal cancer (0.66 HR) —

Go here to see the original:
HUTCHMED Highlights Phase III FRESCO-2 MRCT Data Summary of Fruquintinib in Refractory Metastatic Colorectal Cancer from the Upcoming ESMO 2022...

Basel/Allschwil, Switzerland, September 08, 2022

Original post:
Basilea announces sale of preclinical oncology program to Nodus Oncology

Zurich, Switzerland, September 8, 2022 - Vaccentis AG, a clinical-stage Swiss biopharmaceutical company developing patient-specific medicines, today announced the appointment of the experienced life science executive Mario Stark as Chief Sales and Marketing Officer, effective immediately.

See original here:
Vaccentis strengthens leadership with appointment of Mario Stark as Chief Sales and Marketing Officer

SAINT-HERBLAIN, France and CAMBRIDGE, Mass. (September 8, 2022) – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (Valneva) and VBI Vaccines Inc. (Nasdaq: VBIV) (VBI) today announced a partnership in select European markets for the marketing and distribution of PreHevbri® [Hepatitis B vaccine (recombinant, adsorbed)], the only 3-antigen hepatitis B vaccine approved in Europe.

The rest is here:
Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®

SAN DIEGO, Aug. 29, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for the initiation of a Phase 1/2 clinical trial of YH001 in combination with envafolimab and doxorubicin for the treatment of sarcoma patients, including patients who have not received prior therapy.

Read this article:
TRACON Pharmaceuticals Announces Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with...

BOSTON & LONDON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced that members of its management team will participate in the following investor conferences:

Original post:
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences